

NON-DRUG PAIN MANAGEMENT PROVEN TO REDUCE PAIN AND IMPROVE QUALITY OF LIFE


RegenesiS Biomedical has Patient Care Coordinators Who Track Patient Outcomes, Ensuring Appropriate Prescribing

February 2019 News Update


The Veterans Affairs Central Office (VACO) established guidelines for appropriate Provant Therapy prescribing. Provant[®] Therapy is typically a short-term treatment. Most patients treat 120 days in facilities following this VACO guidance. 98% of patients following the 120-day policy only have one course of care.

Based upon 951 patients who adhered to the VACO policy: 75% of the patients had a decrease in pain. Of the 25% that did not have a decrease in pain, 72% had improvement in their daily activities and 47% had improvement in sleep.


75% of Patients Had a Decrease in Pain Score During Their Course of Provant[®] Therapy



Of the 25% of Patients not having a Decrease in Pain Score, 72% had Improvement in Daily Activities



Of the 25% of Patients not having a Decrease in Pain Score, 47% had Improvement in Sleep



Regenesi Biomedical has Patient Care Coordinators who track patient outcomes, including pain relief and quality of life. We can assist with a protocol for managing Provant Therapy so that outcomes are tracked. If a patient does not have improvement, Regenesi has the Provant Pain Relief Promise...pain relief or the therapy is free.

For postoperative pain relief, consider Provant Therapy. Provant is high-energy, dual-field electromagnetic therapy, proven in clinical trials and patient experiences to provide meaningful pain relief and improved quality of life. We track patient outcomes to provide a full picture of progress with this therapy. To learn more about Provant Therapy and the VACO guidelines, please contact your Regenesi Biomedical representative, or visit www.regenesibio.com.



Keep up with the latest pain management news by clicking these links to follow us on social media:



If you have colleagues that would like to receive these monthly News Updates, please forward this email to them; they may subscribe by emailing us at newsletter@regenesisbio.com